Rocket One Inc. Common Stock (NASDAQ:RKTO) Trading 22.1% Higher – Here’s Why

Rocket One Inc. Common Stock (NASDAQ:RKTO) shot up 22.1% on Wednesday . The stock traded as high as $0.9278 and last traded at $0.90. 2,248,917 shares traded hands during trading, an increase of 704% from the average daily volume of 279,780 shares. The stock had previously closed at $0.7371.

Analysts Set New Price Targets

A number of research analysts recently issued reports on RKTO shares. Wall Street Zen downgraded shares of Rocket One Inc. Common Stock from a “sell” rating to a “strong sell” rating in a research note on Sunday, August 16th. Weiss Ratings downgraded shares of Rocket One Inc. Common Stock from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Wednesday, September 2nd. One investment analyst has rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, the company has a consensus rating of “Hold” and an average target price of $5.00.

Rocket One Inc. Common Stock Trading Up 22.1%

The firm has a market cap of $20.09 million, a PE ratio of -1.10 and a beta of 0.94. The business has a fifty day moving average price of $0.77 and a 200 day moving average price of $0.87.

Rocket One Inc. Common Stock (NASDAQ:RKTO) last posted its earnings results on Friday, August 14th. The company reported ($0.19) earnings per share for the quarter.

Institutional Trading of Rocket One Inc. Common Stock

A hedge fund recently raised its position in Rocket One Inc. Common Stock stock. Lido Advisors LLC lifted its stake in shares of Rocket One Inc. Common Stock (NASDAQ:RKTO) by 100.0% in the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 39,000 shares of the company’s stock after buying an additional 19,500 shares during the quarter. Lido Advisors LLC owned about 0.20% of Rocket One Inc. Common Stock worth $33,000 at the end of the most recent reporting period. Hedge funds and other institutional investors own 7.08% of the company’s stock.

About Rocket One Inc. Common Stock

Hoth Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the acquisition, licensing and development of novel therapies for dermatological, central nervous system and other debilitating conditions. The company’s strategy emphasizes in-licensing late preclinical or early clinical assets with promising pharmacological profiles and leveraging formulation science to optimize delivery. Core to its approach is the design of topical and localized administration platforms intended to enhance drug penetration, sustain release and reduce systemic exposure.

Hoth’s development pipeline encompasses multiple candidate programs addressing high-unmet-need areas such as atopic dermatitis, epidermolysis bullosa and oral mucositis.